Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
PTC is a science-led, global biopharmaceutical company focused on the discovery, d...
PTC is a science-led, global biopharmaceutical ...
Semler Scientific, Inc. is an emerging medical risk-assessment company whose diagn...
Semler Scientific, Inc. is an emerging medical ...
ReWalk Robotics (Nasdaq: RWLK) is an innovative medical device company. We design,...
ReWalk Robotics (Nasdaq: RWLK) is an innovative...
Homology Medicines, Inc. is a genetic medicines company dedicated to transforming ...
Homology Medicines, Inc. is a genetic medicines...
Athenex is a global oncology focused biopharmaceutical company dedicated to the di...
Athenex is a global oncology focused biopharmac...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.